Clinical Trials Browser

Recruiting × OTHER × fluzoparib × Clear all

NCT06255392 2025-08-15

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Phase 3 Recruiting

Fludzoparib" and Anti-angiogenic

NCT06827717 2025-05-31

Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma

Phase 2 Recruiting

Sarcoma, Ewing

NCT06971211 2025-05-14

PARTOM

Phase 2 Recruiting

Prostatic Neoplasms

NCT05894018 2025-05-13

RAFAS-001

Phase 2 Recruiting

Sarcoma

NCT06541314 2024-11-27

Fluzoparib Neoadjuvant Therapy for Ovarian Cancer

Phase 2 Recruiting

Ovarian Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06516445 2024-07-24

SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06413992 2024-05-14

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Phase 2 Recruiting

Neoplasm Metastasis, Recurrence, Endometrial Neoplasms

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3 Recruiting

Breast Neoplasms

NCT05759546 2024-02-06

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Phase 2 Recruiting

Breast Cancer Metastatic

NCT06074692 2023-10-31

PRIMA

Phase 2 Recruiting

Sarcoma, Osteosarcoma

NCT05761470 2023-03-09

IMPARP

Phase 2 Recruiting

Her-2 Negative Breast Cancer